Aldeyra Therapeutics Stock News

Price T Rowe Associates Inc. MD bought a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 11,264 shares of the biotechnology companys stock, valued at approximately $128,000. Several other institutional investors have also modified their []

Brokerages forecast that Aldeyra Therapeutics, Inc (NASDAQ:ALDX) will post earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aldeyra Therapeutics earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.27). Aldeyra Therapeutics posted earnings of ($0.35) []

In last trading session, Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw 1.08 million shares changing hands with its beta currently measuring 1.63. Companys recent per share price level of $7.38 trading at -$0.29 or -3.78% at ring of the bell on the day assigns it a market valuation of $441.10M. That closing price of ALDXs stock is Aldeyra Therapeutics Inc. (NASDAQ:ALDX) Climbs 50.70% In 2021; Is It Attractive Enough At $7.38? Read More »

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 18,039 call options on the company. This represents an increase of approximately 1,205% compared to the typical volume of 1,382 call options. A number of hedge funds have recently added to or reduced their stakes in ALDX. […]

Virtu Financial LLC acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,824 shares of the biotechnology companys stock, valued at approximately $145,000. Several other institutional investors have also recently added to []

Nuveen Asset Management LLC bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 348,125 shares of the biotechnology companys stock, valued at approximately $3,944,000. Nuveen Asset Management LLC owned approximately 0.60% []

JPMorgan Chase & Co. lifted its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 38,795.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,670 shares of the biotechnology companys stock after buying an additional 18,622 shares during the period. JPMorgan Chase & Co.s holdings []

Investors need to pay close attention to Aldeyra (ALDX) stock based on the movements in the options market lately.

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ocular redness scores in the repro

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call Transcript

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).  PVRL is a r

Stellar P values in late stage dry eye disease and allergic conjunctivitis studies.

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participa